WO2013052811A3 - Affenadenorirus (gorilla) or adenoviral vectors and methods of use - Google Patents

Affenadenorirus (gorilla) or adenoviral vectors and methods of use Download PDF

Info

Publication number
WO2013052811A3
WO2013052811A3 PCT/US2012/058978 US2012058978W WO2013052811A3 WO 2013052811 A3 WO2013052811 A3 WO 2013052811A3 US 2012058978 W US2012058978 W US 2012058978W WO 2013052811 A3 WO2013052811 A3 WO 2013052811A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
affenadenorirus
gorilla
methods
adenoviral vectors
Prior art date
Application number
PCT/US2012/058978
Other languages
French (fr)
Other versions
WO2013052811A2 (en
Inventor
Duncan Mcvey
Douglas E. Brough
Jason G.D. Gall
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Priority to EP12775112.1A priority Critical patent/EP2764013B1/en
Priority to US14/349,426 priority patent/US9629906B2/en
Priority to CA2850627A priority patent/CA2850627A1/en
Priority to BR112014008249-9A priority patent/BR112014008249B1/en
Priority to CN201280059668.2A priority patent/CN103974970B/en
Priority to IN3061DEN2014 priority patent/IN2014DN03061A/en
Priority to JP2014534773A priority patent/JP6757120B2/en
Publication of WO2013052811A2 publication Critical patent/WO2013052811A2/en
Publication of WO2013052811A3 publication Critical patent/WO2013052811A3/en
Priority to US15/492,016 priority patent/US10272162B2/en
Priority to US16/352,459 priority patent/US10792376B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Abstract

The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
PCT/US2012/058978 2011-10-05 2012-10-05 Adenoviral vectors and methods of use WO2013052811A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP12775112.1A EP2764013B1 (en) 2011-10-05 2012-10-05 Adenoviral vectors and methods of use
US14/349,426 US9629906B2 (en) 2011-10-05 2012-10-05 Affenadenovirus (gorilla) or adenoviral vectors and methods of use
CA2850627A CA2850627A1 (en) 2011-10-05 2012-10-05 Affenadenovirus (gorilla) or adenoviral vectors and methods of use
BR112014008249-9A BR112014008249B1 (en) 2011-10-05 2012-10-05 Adenovirus or adenoviral vector and composition with the same
CN201280059668.2A CN103974970B (en) 2011-10-05 2012-10-05 Monkey adenovirus (gorilla) or adenovirus vector and its application method
IN3061DEN2014 IN2014DN03061A (en) 2011-10-05 2012-10-05
JP2014534773A JP6757120B2 (en) 2011-10-05 2012-10-05 Afen adenovirus (gorilla) or adenovirus vector, and how to use
US15/492,016 US10272162B2 (en) 2011-10-05 2017-04-20 Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US16/352,459 US10792376B2 (en) 2011-10-05 2019-03-13 Affenadenovirus (gorilla) or adenoviral vectors and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543652P 2011-10-05 2011-10-05
US61/543,652 2011-10-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/349,426 A-371-Of-International US9629906B2 (en) 2011-10-05 2012-10-05 Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US15/492,016 Continuation US10272162B2 (en) 2011-10-05 2017-04-20 Affenadenovirus (gorilla) or adenoviral vectors and methods of use

Publications (2)

Publication Number Publication Date
WO2013052811A2 WO2013052811A2 (en) 2013-04-11
WO2013052811A3 true WO2013052811A3 (en) 2013-06-20

Family

ID=47045180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/058978 WO2013052811A2 (en) 2011-10-05 2012-10-05 Adenoviral vectors and methods of use

Country Status (9)

Country Link
US (3) US9629906B2 (en)
EP (1) EP2764013B1 (en)
JP (2) JP6757120B2 (en)
CN (2) CN103974970B (en)
BR (1) BR112014008249B1 (en)
CA (1) CA2850627A1 (en)
HK (1) HK1252010A1 (en)
IN (1) IN2014DN03061A (en)
WO (1) WO2013052811A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987726B (en) 2011-10-05 2017-10-03 金维克有限公司 Monkey (gorilla) adenovirus or adenovirus vector and its application method
WO2013052859A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN103974970B (en) 2011-10-05 2018-01-02 金维克有限公司 Monkey adenovirus (gorilla) or adenovirus vector and its application method
CA2850629A1 (en) 2011-10-05 2013-04-11 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN117384961A (en) 2016-02-23 2024-01-12 萨克生物研究学院 Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
BR112019010275A2 (en) 2016-12-09 2019-09-17 Glaxosmithkline Biologicals Sa recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus
CN110062630A (en) 2016-12-12 2019-07-26 萨克生物研究学院 Cancer target synthesizes adenovirus and application thereof
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
EP3655539A1 (en) 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
EP3762010A4 (en) 2018-03-06 2022-04-06 Precigen, Inc. Hepatitis b vaccines and uses of the same
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
CA3170369A1 (en) 2020-03-05 2022-04-14 Michal Shahar Methods and compositions for treating cancer with immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051367A1 (en) * 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
WO2011057248A2 (en) * 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
WO1995002697A1 (en) 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (en) 1994-06-10 2006-12-14 Genvec, Inc. ADENOVER VECTOR SYSTEMS AND CELL LINES
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69638058D1 (en) 1995-06-15 2009-11-26 Crucell Holland Bv Packaging systems for human recombinant adenoviruses for gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP0885012A4 (en) 1996-01-29 2001-09-05 Univ Georgetown Malaria vaccine based upon the addition of a msa1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU779892B2 (en) * 1999-08-27 2005-02-17 European Molecular Biology Laboratory Modified adenoviral fibre and uses thereof
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
SG165153A1 (en) * 2001-11-21 2010-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
CA2993042A1 (en) * 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
DE602005025512D1 (en) * 2004-10-13 2011-02-03 Crucell Holland Bv IMPROVED ADENOVIRUS VECTORS AND THEIR USE
MX2007007145A (en) 2004-12-13 2007-08-20 Canji Inc Cell lines for production of replication-defective adenovirus.
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
WO2008011609A2 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
ES2898235T3 (en) 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid and amino acid sequences, vectors containing them, and their uses
EP2459716B1 (en) 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CA2850629A1 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
CN103987726B (en) * 2011-10-05 2017-10-03 金维克有限公司 Monkey (gorilla) adenovirus or adenovirus vector and its application method
CN103974970B (en) * 2011-10-05 2018-01-02 金维克有限公司 Monkey adenovirus (gorilla) or adenovirus vector and its application method
WO2013052859A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
US20150157700A1 (en) 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
EP2855511B1 (en) * 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051367A1 (en) * 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
WO2011057248A2 (en) * 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. WEVERS ET AL: "Novel Adenoviruses in Wild Primates: a High Level of Genetic Diversity and Evidence of Zoonotic Transmissions", JOURNAL OF VIROLOGY OCT.2011, vol. 85, no. 20, 10 August 2011 (2011-08-10), pages 10774 - 10784, XP055048541, ISSN: 0022-538X, DOI: 10.1128/JVI.00810-11 *
ROY SOUMITRA ET AL: "Isolation and Characterisation of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 5, no. 7, 1 July 2009 (2009-07-01), pages 1 - 9, XP002548489, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000503 *
WEVERS DIANA ET AL: "A novel adenovirus of Western lowland gorillas (Gorilla gorilla gorilla)", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 5 November 2010 (2010-11-05), pages 303, XP021080233, ISSN: 1743-422X, DOI: 10.1186/1743-422X-7-303 *

Also Published As

Publication number Publication date
JP6970060B2 (en) 2021-11-24
CN103974970B (en) 2018-01-02
JP6757120B2 (en) 2020-09-16
JP2014530605A (en) 2014-11-20
BR112014008249B1 (en) 2022-03-15
US20170246318A1 (en) 2017-08-31
US20140248308A1 (en) 2014-09-04
US9629906B2 (en) 2017-04-25
EP2764013B1 (en) 2022-01-26
US10272162B2 (en) 2019-04-30
US10792376B2 (en) 2020-10-06
CA2850627A1 (en) 2013-04-11
WO2013052811A2 (en) 2013-04-11
BR112014008249A2 (en) 2017-04-18
US20190269794A1 (en) 2019-09-05
IN2014DN03061A (en) 2015-05-15
HK1252010A1 (en) 2019-05-10
CN103974970A (en) 2014-08-06
CN107937440A (en) 2018-04-20
JP2018198603A (en) 2018-12-20
EP2764013A2 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
WO2013052811A3 (en) Affenadenorirus (gorilla) or adenoviral vectors and methods of use
WO2013052799A3 (en) Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013052832A3 (en) Simian (gorilla) adenovirus or adenoviral vectors and methods of use
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
WO2015168547A3 (en) In vivo gene engineering with adenoviral vectors
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
WO2011057248A3 (en) Methods of propagating monkey adenoviral vectors
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2015013313A3 (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP2274442A4 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2013057141A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2012071318A3 (en) Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
WO2013173702A3 (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
IL228328B (en) Capsid-free aav vectors, compositions and methods for vector production and gene delivery
WO2013057143A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX367100B (en) Aav vector compositions and methods for gene transfer to cells, organs and tissues.
EP3321367A3 (en) Vector
WO2012027572A3 (en) Methods for nucleic acid capture and sequencing
EP2152883A4 (en) Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2014018601A3 (en) New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
WO2012083297A3 (en) Adenoviral vectors with modified hexon regions
WO2008048976A3 (en) Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
SG11201705820UA (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
IN2014CN03187A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12775112

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2850627

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012775112

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14349426

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014534773

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014008249

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014008249

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140404